JP2022523710A5 - - Google Patents

Info

Publication number
JP2022523710A5
JP2022523710A5 JP2021544141A JP2021544141A JP2022523710A5 JP 2022523710 A5 JP2022523710 A5 JP 2022523710A5 JP 2021544141 A JP2021544141 A JP 2021544141A JP 2021544141 A JP2021544141 A JP 2021544141A JP 2022523710 A5 JP2022523710 A5 JP 2022523710A5
Authority
JP
Japan
Prior art keywords
antibody
cdr2
cdr1
optionally
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021544141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523710A (ja
JP7656330B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014425 external-priority patent/WO2020159754A2/en
Publication of JP2022523710A publication Critical patent/JP2022523710A/ja
Publication of JP2022523710A5 publication Critical patent/JP2022523710A5/ja
Application granted granted Critical
Publication of JP7656330B2 publication Critical patent/JP7656330B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021544141A 2019-01-28 2020-01-21 Cd44に特異的な抗体 Active JP7656330B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/073402 2019-01-28
CN2019073402 2019-01-28
PCT/US2020/014425 WO2020159754A2 (en) 2019-01-28 2020-01-21 Antibodies specific to cd44

Publications (3)

Publication Number Publication Date
JP2022523710A JP2022523710A (ja) 2022-04-26
JP2022523710A5 true JP2022523710A5 (enExample) 2023-02-01
JP7656330B2 JP7656330B2 (ja) 2025-04-03

Family

ID=71840370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544141A Active JP7656330B2 (ja) 2019-01-28 2020-01-21 Cd44に特異的な抗体

Country Status (7)

Country Link
US (1) US12311031B2 (enExample)
EP (1) EP3917952A4 (enExample)
JP (1) JP7656330B2 (enExample)
CN (1) CN113474362B (enExample)
AU (1) AU2020216780B2 (enExample)
TW (1) TWI870378B (enExample)
WO (1) WO2020159754A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4350317A4 (en) * 2021-05-28 2024-10-02 NSK Ltd. ROLLING DEVICE STATE DETECTION METHOD, DETECTION DEVICE, AND PROGRAM
CN114213538B (zh) * 2021-12-24 2022-07-08 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114316049B (zh) * 2021-12-24 2022-08-09 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US20260166169A1 (en) * 2022-10-19 2026-06-18 Multitude Therapeutics Inc. Antibody-drug conjugate, preparation method and use thereof
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2164728A1 (en) * 1993-06-22 1995-01-05 Helmut Ponta Processes for diagnosing and analysing tumours
JP2007510735A (ja) * 2003-11-07 2007-04-26 ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Cd44グリコフォームに対する抗体およびその使用
US20080171042A1 (en) * 2004-05-07 2008-07-17 University Of Florida Research Foundation, Inc. Cd44 Variants As Therapeutic Targets
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
WO2011022335A1 (en) * 2009-08-21 2011-02-24 Mount Sinai School Of Medicine Of New York University Methods of using cd44 fusion proteins to treat cancer
PT3575315T (pt) * 2014-09-15 2022-12-16 Agc Biologics S P A Recetores de antigénios quiméricos
US20170014524A1 (en) * 2015-07-15 2017-01-19 The California Institute For Biomedical Research Auristatin-antibody conjugates and uses thereof
IL258491B2 (en) * 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
AU2017239637A1 (en) * 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN113896793B (zh) * 2021-09-30 2023-05-26 港科鹏禾生物(苏州)有限公司 一种抗人il-17rc的单克隆抗体及其应用

Similar Documents

Publication Publication Date Title
JP2021531825A5 (enExample)
JP2022514693A5 (enExample)
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
KR102749049B1 (ko) 분자를 표적화하기 위한 항원 결합 구조체
JP2022541435A5 (enExample)
JP2021531826A5 (enExample)
JP2020501531A5 (enExample)
JP2018532383A5 (enExample)
JP2019531084A5 (enExample)
JP2020525032A5 (enExample)
JP2018532766A5 (enExample)
JP2019512207A5 (enExample)
JP2022533538A5 (enExample)
JP2012504401A (ja) 抗cxcr4抗体および癌治療のためのそれらの使用
JP2020534012A5 (enExample)
JP2024001073A5 (enExample)
TW202200618A (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
JP2018522888A5 (enExample)
JP2021521793A5 (enExample)
JP2022542559A5 (enExample)
JP2023543493A5 (enExample)
JP2020515277A5 (enExample)
JP2022514786A5 (enExample)
JP2023524102A5 (enExample)
JP2025026839A5 (enExample)